A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 31, 2004

Study Completion Date

October 31, 2005

Conditions
Soft Tissue Sarcoma
Interventions
DRUG

STA-4783

Trial Locations (27)

10016

NYU Cancer Institute Clinical Center, New York

10032

Herbert Irving Cancer Center, New York

15232

Hillman Cancer Center, Pittsburgh

28203

Carolinas Medical Center/Blumenthal Cancer Center, Charlotte

30322

Winship Cancer Institute, Atlanta

32610

University of Florida, Gainesville

33401

Palm Beach Cancer Institute, West Palm Beach

33612

H. Lee Moffitt Cancer Center, Tampa

37203

The Sarah Cannon Cancer Center, Nashville

38120

The West Clinic, Memphis

40202

University of Louisville Hospital, Louisville

48109

University of Michigan, Ann Arbor

48201

Wayne State University, Detroit

48503

Genesys Hurley Cancer Institute, Flint

60637

University of Chicago Department of Medicine, Chicago

63110

Washington University School of Medicine, St Louis

67214

Via Christi Regional Med. Center (Wichita CCOP), Wichita

68198

University of Nebraska Medical Center, Omaha

71103

Feist-Weiller Cancer Center, Shreveport

77030

MD Anderson Cancer Center, Houston

85258

Arizona Cancer Center, Scottsdale

85724

Arizona Cancer Center, Tucson

90095

UCLA, Los Angeles

97239

Oregon Health and Science University, Portland

06520

Yale University School of Medicine, New Haven

02115

Dana-Farber Cancer Institute, Boston

M5G 1X5

Mount Sinai Hospital, Toronto

All Listed Sponsors
lead

Synta Pharmaceuticals Corp.

INDUSTRY